Mymetics Corporation (MYMX)

Market Cap	46.00
Revenue (ttm)	564.14K
Net Income (ttm)	-12.24M
Shares Out	151.88K
EPS (ttm)	-80.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	386
Open	0.0003
Previous Close	0.0003
Day's Range	0.0003 - 0.0003
52-Week Range	0.0003 - 0.0003
Beta	2.36
RSI	37.20
Earnings Date	n/a

About Mymetics

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: MYMX

Financial Performance

In 2022, Mymetics's revenue was 1.03 million, an increase of 139.07% compared to the previous year's 430,000. Losses were -4.81 million, 1.59% more than in 2021.

Financial numbers in EUR